Literature DB >> 20416374

Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer.

Benito Casu1, Annamaria Naggi, Giangiacomo Torri.   

Abstract

The heparan sulfate (HS) chains of heparan sulfate proteoglycans (HSPG) are "ubiquitous" components of the cell surface and the extracellular matrix (EC) and play important roles in the physiopathology of developmental and homeostatic processes. Most biological properties of HS are mediated by interactions with "heparin-binding proteins" and can be modulated by exogenous heparin species (unmodified heparin, low molecular weight heparins, shorter heparin oligosaccharides and various non-anticoagulant derivatives of different sizes). Heparin species can promote or inhibit HS activities to different extents depending, among other factors, on how closely their structure mimics the biologically active HS sequences. Heparin shares structural similarities with HS, but is richer in "fully sulfated" sequences (S domains) that are usually the strongest binders to heparin/HS-binding proteins. On the other hand, HS is usually richer in less sulfated, N-acetylated sequences (NA domains). Some of the functions of HS chains, such as that of activating proteins by favoring their dimerization, often require short S sequences separated by rather long NA sequences. The biological activities of these species cannot be simulated by heparin, unless this polysaccharide is appropriately chemically/enzymatically modified or biotechnologically engineered. This mini review covers some information and concepts concerning the interactions of HS chains with heparin-binding proteins and some of the approaches for modulating HS interactions relevant to inflammation and cancer. This is approached through a few illustrative examples, including the interaction of HS and heparin-derived species with the chemokine IL-8, the growth factors FGF1 and FGF2, and the modulation of the activity of the enzyme heparanase by these species. Progresses in sequencing HS chains and reproducing them either by chemical synthesis or semi-synthesis, and in the elucidation of the 3D structure of oligosaccharide-protein complexes, are paving the way for rational approaches to the development of HS-inspired drugs in the field of inflammation and cancer, as well in other therapeutic fields.
Copyright © 2010 International Society of Matrix Biology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20416374      PMCID: PMC3057403          DOI: 10.1016/j.matbio.2010.04.003

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  106 in total

Review 1.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

2.  Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2.

Authors:  Xingbin Ai; Anh-Tri Do; Marion Kusche-Gullberg; Ulf Lindahl; Ke Lu; Charles P Emerson
Journal:  J Biol Chem       Date:  2005-12-23       Impact factor: 5.157

3.  VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase.

Authors:  Christopher J Robinson; Barbara Mulloy; John T Gallagher; Sally E Stringer
Journal:  J Biol Chem       Date:  2005-10-28       Impact factor: 5.157

Review 4.  Multiprotein signalling complexes: regional assembly on heparan sulphate.

Authors:  J T Gallagher
Journal:  Biochem Soc Trans       Date:  2006-06       Impact factor: 5.407

Review 5.  Non-anticoagulant heparins and inhibition of cancer.

Authors:  Benito Casu; Israel Vlodavsky; Ralph D Sanderson
Journal:  Pathophysiol Haemost Thromb       Date:  2009-01-27

Review 6.  The structure of glycosaminoglycans and their interactions with proteins.

Authors:  Neha S Gandhi; Ricardo L Mancera
Journal:  Chem Biol Drug Des       Date:  2008-12       Impact factor: 2.817

Review 7.  Advances in the separation, sensitive detection, and characterization of heparin and heparan sulfate.

Authors:  Albert K Korir; Cynthia K Larive
Journal:  Anal Bioanal Chem       Date:  2008-10-09       Impact factor: 4.142

8.  Glycosaminoglycan affinity of the complete fibroblast growth factor family.

Authors:  Masahiro Asada; Michiyo Shinomiya; Masashi Suzuki; Emi Honda; Rika Sugimoto; Masahiko Ikekita; Toru Imamura
Journal:  Biochim Biophys Acta       Date:  2008-09-16

9.  Control of growth factor networks by heparan sulfate proteoglycans.

Authors:  Kimberly Forsten-Williams; Chia Lin Chu; Michael Fannon; Jo Ann Buczek-Thomas; Matthew A Nugent
Journal:  Ann Biomed Eng       Date:  2008-10-07       Impact factor: 3.934

10.  Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy.

Authors:  Sara Guglier; Milos Hricovíni; Rahul Raman; Laura Polito; Giangiacomo Torri; Benito Casu; Ram Sasisekharan; Marco Guerrini
Journal:  Biochemistry       Date:  2008-12-30       Impact factor: 3.162

View more
  44 in total

1.  Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments.

Authors:  Anna Alekseeva; Benito Casu; Giuseppe Cassinelli; Marco Guerrini; Giangiacomo Torri; Annamaria Naggi
Journal:  Anal Bioanal Chem       Date:  2013-11-20       Impact factor: 4.142

2.  Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin.

Authors:  Jong Youn Baik; Hussain Dahodwala; Eziafa Oduah; Lee Talman; Trent R Gemmill; Leyla Gasimli; Payel Datta; Bo Yang; Guoyun Li; Fuming Zhang; Lingyun Li; Robert J Linhardt; Andrew M Campbell; Stephen F Gorfien; Susan T Sharfstein
Journal:  Biotechnol J       Date:  2015-06-24       Impact factor: 4.677

3.  Heparan sulfate differences in rheumatoid arthritis versus healthy sera.

Authors:  Jenny K Sabol; Wei Wei; Marcos López-Hoyos; Youjin Seo; Armann Andaya; Julie A Leary
Journal:  Matrix Biol       Date:  2014-09-11       Impact factor: 11.583

Review 4.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

5.  Blood management-issues: the panic of coagulopathic bleeding--is there a rational approach?

Authors:  Bruce D Spiess
Journal:  J Extra Corpor Technol       Date:  2011-03

6.  Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo.

Authors:  Maura Poli; Michela Asperti; Annamaria Naggi; Natascia Campostrini; Domenico Girelli; Michela Corbella; Marina Benzi; Celine Besson-Fournier; Helene Coppin; Federica Maccarinelli; Dario Finazzi; Paolo Arosio
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

Review 7.  Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.

Authors:  Achilleas D Theocharis; Chrisostomi Gialeli; Panagiotis Bouris; Efstathia Giannopoulou; Spyros S Skandalis; Alexios J Aletras; Renato V Iozzo; Nikos K Karamanos
Journal:  FEBS J       Date:  2014-11-06       Impact factor: 5.542

8.  Structure-activity relationship study of WSS25 derivatives with anti-angiogenesis effects.

Authors:  Xia Chen; Fei Xiao; Ying Wang; Jianping Fang; Kan Ding
Journal:  Glycoconj J       Date:  2012-07-31       Impact factor: 2.916

9.  Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.

Authors:  Joyce N Gonzales; Kyung-mi Kim; Marina A Zemskova; Ruslan Rafikov; Brenten Heeke; Matthew N Varn; Stephen Black; Thomas P Kennedy; Alexander D Verin; Evgeny A Zemskov
Journal:  Vascul Pharmacol       Date:  2014-01-25       Impact factor: 5.773

10.  Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides.

Authors:  Anna Alekseeva; Benito Casu; Giangiacomo Torri; Sabrina Pierro; Annamaria Naggi
Journal:  Anal Biochem       Date:  2012-11-29       Impact factor: 3.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.